Health & Medical · Week of Nov 2, 2026
Vantive, Rockwell Medical strike dialysis deal: the week in health
Also: Zylox-Tonbridge and GL Capital invest in LifeTech Scientific, Illumina wins a Singapore sequencing tender, and NYU Langone presents AHA studies.
Deal activity in medical devices led the week. Vantive agreed to sell most of its hemodialysis business to Rockwell Medical, saying it will concentrate on home dialysis and critical care. In Hong Kong, Zylox-Tonbridge and GL Capital announced a joint investment of approximately HK$1.482 billion in LifeTech Scientific, with Zylox-Tonbridge saying it intends to pursue a potential merger. Illumina said it won an international tender to sequence genomes for Singapore's SG-INSIGHT study, which is expected to include about 450,000 people.
Clinical research centred on the American Heart Association's Scientific Sessions, where NYU Langone Health presented two studies. One found no long-term survival advantage for routine invasive procedures over drug therapy in stable heart disease. The other linked bedroom HEPA filtration to smaller blood sugar swings in prediabetes. Elsewhere, Elanco and Nootropics Depot each released company-commissioned consumer and product research, and POMDOCTOR said it had regained compliance with Nasdaq's bid price rule.

Elanco Animal Health
October Consumer Research Confirms Pet Health Remains Non-Negotiable Household Priority
Elanco Animal Health released an October survey of 2,018 U.S. adults, including 1,495 dog and cat owners, in which 93% of pet owners said they maintained or increased pet spending over the past three months and 7 percent of consumers said they would cut pet health spending under economic pressure. The company-commissioned survey also found 38% of pet owners have shifted medication purchasing outside the clinic in the past year or two, which bears on veterinary distribution channels.

VANTIVE US HEALTHCARE LLC
Vantive Announces Agreement to Divest Majority of Hemodialysis Assets and Associated Operations to Rockwell Medical
Vantive agreed to divest the majority of its hemodialysis business, including concentrates, HD monitors, water treatment systems and its Medolla, Italy manufacturing facility, to Rockwell Medical, with closing expected in mid-2027 subject to regulatory approvals. The dialyzer portfolio, including Theranova, is excluded, and Vantive says the move sharpens its focus on home dialysis and critical care.

Illumina, Inc.
Illumina selected to help bring precision medicine into everyday healthcare in Singapore
Illumina said it was selected through an international competitive tender to provide whole-genome sequencing for SG-INSIGHT, a cohort under Phase III of Singapore's National Precision Medicine programme expected to include approximately 450,000 individuals. The study aims to link genomic and real-world health data and support genetic screening in Singapore's public healthcare system, and the release does not state a start date.
POMDOCTOR LIMITED
POMDOCTOR LIMITED Regains Compliance with Nasdaq Bid Price Requirement
POMDOCTOR LIMITED said Nasdaq confirmed on November 5, 2026 that it has regained compliance with the $1.00 minimum bid price requirement, following an October 6, 2026 delisting determination. The Nasdaq Hearings Panel hearing set for November 12, 2026 has been cancelled, and the Class A ordinary shares will continue trading under "POM."

ZYLOX-TONBRIDGE
Zylox-Tonbridge and GL Capital Announce Strategic Investment in LifeTech Scientific to Build a Leading Vascular and Structural Heart Intervention Platform
Zylox-Tonbridge and GL Capital will jointly invest approximately HK$1.482 billion through GL Lighthouse Two Investment Limited for about 16.7% of LifeTech Scientific, making the vehicle LifeTech's largest single shareholder. GL Capital will also subscribe for 39.8 million new Zylox-Tonbridge shares at HK$22 each, and Zylox-Tonbridge says it intends to pursue a potential merger with LifeTech, with no completion date given.

NYU Grossman School of Medicine and NYU Langone Health
Routine Invasive Procedures for Stable Heart Disease Offer No Long-Term Survival Advantage Over Drug Therapy
NYU Langone Health researchers reported in ISCHEMIA-EXTEND, which followed more than 5,000 patients with stable coronary artery disease, that early routine stents or bypass surgery did not improve survival over medications and lifestyle changes, with a 26 percent chance of death versus 27 percent after nearly a decade. The results were presented November 7, 2026 at the AHA Scientific Sessions and published in JAMA, though the extended analysis did not track nonfatal heart attacks, repeat procedures or quality of life.

Nootropics Depot
Nootropics Depot Publishes Retail Market Research Measuring 68 Products Across 8 Ingredients
Nootropics Depot published lab results comparing 68 retail supplement products across 8 ingredients, 15 of them its own, tested in its Tempe, Ariz. lab from Q1 2025 through Q4 2025. The company reports that 6 of 10 competing lion's mane products measured no erinacine A, and it notes one case where a competing Cistanche product measured higher echinacoside than its own.

NYU Grossman School of Medicine and NYU Langone Health
Cleaner Bedroom Air May Help Manage Blood Sugar in Prediabetes
NYU Langone Health reported that in a randomized study of more than 150 New York City adults with prediabetes, real bedroom HEPA filters cut tiny air particles by 36 percent and were linked to a nearly 8 percent drop in daily blood sugar swings compared with sham filters. The results are being presented November 8, 2026 at the AHA Scientific Sessions, and the researchers say the findings may not apply to people with diabetes or in regions with different pollution.
This roundup is written with AI assistance from the press releases listed above, using only what they state. The releases are the companies' own announcements, not The Digest Lab reporting.